Novel Radiobiological Gamma Index for Evaluation of 3-Dimensional Predicted Dose Distribution.
OBJECTIVE
To propose a gamma index-based dose evaluation index that integrates the radiobiological parameters of tumor control (TCP) and normal tissue complication probabilities (NTCP).


METHODS
Fifteen prostate and head and neck (H&N) cancer patients received intensity modulated radiation therapy. Before treatment, patient-specific quality assurance was conducted via beam-by-beam analysis, and beam-specific dose error distributions were generated. The predicted 3-dimensional (3D) dose distribution was calculated by back-projection of relative dose error distribution per beam. A 3D gamma analysis of different organs (prostate: clinical [CTV] and planned target volumes [PTV], rectum, bladder, femoral heads; H&N: gross tumor volume [GTV], CTV, spinal cord, brain stem, both parotids) was performed using predicted and planned dose distributions under 2%/2 mm tolerance and physical gamma passing rate was calculated. TCP and NTCP values were calculated for voxels with physical gamma indices (PGI) >1. We propose a new radiobiological gamma index (RGI) to quantify the radiobiological effects of TCP and NTCP and calculate radiobiological gamma passing rates.


RESULTS
The mean RGI gamma passing rates for prostate cases were significantly different compared with those of PGI (P<.03-.001). The mean RGI gamma passing rates for H&N cases (except for GTV) were significantly different compared with those of PGI (P<.001). Differences in gamma passing rates between PGI and RGI were due to dose differences between the planned and predicted dose distributions. Radiobiological gamma distribution was visualized to identify areas where the dose was radiobiologically important.


CONCLUSIONS
RGI was proposed to integrate radiobiological effects into PGI. This index would assist physicians and medical physicists not only in physical evaluations of treatment delivery accuracy, but also in clinical evaluations of predicted dose distribution.
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan. Electronic address: sumida@radonc.med.osaka-u.ac.jp.
Iori
I
Sumida
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Hajime
H
Yamaguchi
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Hisao
H
Kizaki
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Keiko
K
Aboshi
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Mari
M
Tsujii
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Nobuhiko
N
Yoshikawa
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Yuji
Y
Yamada
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Osamu
O
Suzuki
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yuji
Y
Seo
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Fumiaki
F
Isohashi
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yasuo
Y
Yoshioka
Department of Radiation Oncology, NTT West Osaka Hospital, Osaka, Japan.
Kazuhiko
K
Ogawa
D000465:Algorithms; D005270:Femur Head / Q000528:radiation effects; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D058958:Organs at Risk / Q000000981:diagnostic imaging / Q000528:radiation effects*; D010306:Parotid Gland / Q000528:radiation effects; D011467:Prostate / Q000528:radiation effects; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care; D011859:Radiography; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods* / Q000592:standards; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods* / Q000592:standards; D012007:Rectum / Q000528:radiation effects; D013116:Spinal Cord; D001743:Urinary Bladder / Q000528:radiation effects